Immunotherapy of cancer in the era of checkpoint inhibitor

被引：0
作者：
Inderjit Mehmi
Omid Hamid
机构：
[1] The Angeles Clinic and Research Institute,
[2] Cedar Sinai Affiliate,undefined
来源：
Clinical & Experimental Metastasis | 2022年 / 39卷
关键词：
Melanoma; cSCC; MCC; Immunotherapy; Checkpoint inhibitors; TIM-3; LAG-3; Cytokines; NSCLC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Application of immunotherapy has revolutionized treatment of number of malignancies. We present a review of immunotherapy approaches, early-phase data of number of new immunotherapeutic targets in melanoma, cutaneous squamous cell carcinoma, Merkel cell cancer, and non-small cell lung cancer.
引用
收藏
页码：231 / 237
页数：6
相关论文
共 193 条
  • [1] Curran MA(2010)PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc Natl Acad Sci USA 107 4275-4280
  • [2] Montalvo W(2015)Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 23-34
  • [3] Yagita H(2015)Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 372 2006-2017
  • [4] Allison JP(2005)Blockade of B7–H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res 65 1089-1096
  • [5] Larkin J(2012)Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape Cancer Res 72 917-927
  • [6] Chiarion-Sileni V(2019)A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): interim safety, efficacy, and pharmacokinetic finding in advanced cancers J Clin Oncol 37 12-12
  • [7] Gonzalez R(2018)Pushing the accelerator and releasing the brake: a phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma J Clin Oncol 36 3012-3012
  • [8] Grob JJ(2018)Phase I/II study of LAG525+/_spartalizumab (PDR001) in patients (pts) with advanced malignancies J Clin Oncol 4 172-36
  • [9] Cowey CL(2016)Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies J ImmunoTher Cancer 23 1929-23
  • [10] Lao CD(2017)Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody Clin Cancer Res 24 1816-74
12345678910